[
    {
        "pregunta": "1. What poor prognostic factors indicate severe PsA disease?",
        "respuesta": "Poor prognostic factors that indicate severe psoriatic arthritis (PsA) disease include:\n\n- Erosive disease  \n- Elevated levels of inflammation markers such as C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) attributable to PsA\n\nThese factors, alone or in combination with other features like long-term damage interfering with function or highly active disease causing significant impairment in quality of life, help define severe PsA.",
        "contexto": [
            "care providers and patients should judge PsA and psoriasis severity on a case-bycase basis. For the purpose of these recommendations, severity includes not only the level of disease activity at a given time point, but also the presence or absence of poor prognostic factors and long-term damage. Examples of severe PsA disease include the presence of 1 or more of the following: a poor prognostic factor (erosive disease, dactylitis, elevated levels of inflammation mark-ers such as ESR and CRP",
            "of severe PsA disease include the presence of ≥1 of the following: a poor prognostic factor (erosive disease, elevated levels of inflammation markers such as C-reactive protein or erythrocyte sedimentation rate attributable to PsA), long-term damage that interferes with function (e.g., joint deformities, vision loss), highly active disease that causes major impairment in quality of life (i.e., active psoriatic inflammatory disease at many sites [including dactylitis, enthesitis] or",
            "it encompasses the level of disease activity at a given time point, as well as the presence of poor prognostic factors and long-term damage. Examples of severe PsA disease include the presence of ≥1 of the following: a poor prognostic factor (erosive disease, elevated levels of inflammation markers such as C-reactive protein or erythrocyte sedimentation rate attributable to PsA), long-term damage that interferes with function (e.g., joint deformities, vision loss), highly active disease that",
            "damage. Examples of severe PsA disease include the presence of ≥1 of the following: a poor prognostic factor (erosive disease, elevated levels of inflammation markers such as C-reactive protein or erythrocyte sedimentation rate attributable to PsA), long-term damage that interferes with function (e.g., joint deformities, vision loss), highly active disease that causes major impairment in quality of life (i.e., active psoriatic inflammatory disease at many sites [including dactylitis,",
            "activity in that it encompasses the level of disease activity at a given time point, as well as the presence of poor prognostic factors and long-term damage. Examples of severe PsA disease include the presence of ≥1 of the following: a poor prognostic factor (erosive disease, elevated levels of inflammation markers such as C-reactive protein or erythrocyte sedimentation rate attributable to PsA), long-term damage that interferes with function (e.g., joint deformities, vision loss), highly"
        ]
    },
    {
        "pregunta": "2. How should treatment decisions be approached given the conditional nature of many recommendations?",
        "respuesta": "Clinicians should approach treatment decisions with shared decision-making that incorporates patient preferences, values, and individual clinical circumstances. Because many treatment recommendations are conditional—reflecting uncertainty about the balance of benefits and harms or variability in patient situations—clinicians need to use clinical judgment and engage patients in discussing the risks, benefits, and alternatives of therapies. Treatment recommendations serve as guidance for the typical patient but should not be used to restrict access to therapies or mandate a specific sequence of treatments. Personalized care and flexibility are essential when applying conditional recommendations.",
        "contexto": [
            "recommendation denotes uncertainty regarding the balance of benefits and harms, such as when the evidence quality is low or very low, or when the decision is sensitive to individual patient preferences, or when costs are expected to impact the decision. Thus, conditional recommendations refer to decisions in which incorporation of patient preferences is a particularly essential element of decision-making. Examples of each class of pharmacologic intervention addressed in the recommendations are",
            "would apply to all or almost all patients, and only a small proportion of clinicians/patients not wanting to follow the recommendation. We use the phrase \"should use\" or \"should be used\" for strong recommendations. 2. A conditional recommendation means that the panel believed the desirable effects of following the recommendation probably outweigh the undesirable effects, so the course of action would apply to the majority of the patients, but a small proportion of clinicians/patients may not",
            "of the patients, but a small proportion of clinicians/patients may not want to follow the recommendation. Because of this, conditional recommendations are preference sensitive and always warrant a shared decision-making approach. We use the phrase \"is recommended over\" or \"is/would be recommended\" for conditional recommendations. We specify conditions under which the less preferred drug may be used by using the phrase \"may be used\" or \"may consider\" or \"Y (less preferred drug) may be used",
            "an intervention clearly outweigh the harms (or vice versa); a conditional recommendation denotes uncertainty regarding the balance of benefits and harms, such as when the evidence certainty is low or very low, or when the decision is sensitive to individual patient preferences, or when costs are expected to impact the decision. Thus, conditional recommendations refer to decisions in which incorporation of patient preferences is a particularly essential element of decision-making. Scope",
            "an intervention clearly outweigh the harms (or vice versa); a conditional recommendation denotes uncertainty regarding the balance of benefits and harms, such as when the evidence quality is low or very low, or when costs are expected to impact the decision. Thus, for conditional recommendations, incorporation of patient preferences is particularly essential, acknowledging that patient preferences are an important part of all clinical decision-making. Rosters of the Core Leadership Team,"
        ]
    },
    {
        "pregunta": "3. How does long-term damage, such as joint deformities or vision loss, influence treatment decisions in psoriatic arthritis?",
        "respuesta": "Long-term damage in psoriatic arthritis (PsA), such as joint deformities or vision loss that interferes with function, is recognized as a poor prognostic factor indicating severe disease. The presence of such damage influences treatment decisions by identifying patients who may require more aggressive or targeted therapies to prevent further progression and to manage functional impairment. Because severe disease includes long-term damage interfering with function, these patients typically warrant intensified treatment approaches to control inflammation and limit additional damage.\n\nHowever, since widely agreed-upon definitions of disease severity are lacking, treatment decisions incorporating long-term damage should be individualized and established jointly by the healthcare provider and the patient.",
        "contexto": [
            "long-term damage. Examples of severe PsA disease include the presence of ≥1 of the following: a poor prognostic factor (erosive disease, elevated levels of inflammation markers such as C-reactive protein or erythrocyte sedimentation rate attributable to PsA), long-term damage that interferes with function (e.g., joint deformities, vision loss), highly active disease that causes major impairment in quality of life (i.e., active psoriatic inflammatory disease at many sites [including dactylitis,",
            "long-term damage. Examples of severe PsA disease include the presence of ≥1 of the following: a poor prognostic factor (erosive disease, elevated levels of inflammation markers such as C-reactive protein or erythrocyte sedimentation rate attributable to PsA), long-term damage that interferes with function (e.g., joint deformities, vision loss), highly active disease that causes major impairment in quality of life (i.e., active psoriatic inflammatory disease at many sites [including dactylitis,",
            "long-term damage. Examples of severe PsA disease include the presence of ≥1 of the following: a poor prognostic factor (erosive disease, elevated levels of inflammation markers such as C-reactive protein or erythrocyte sedimentation rate attributable to PsA), long-term damage that interferes with function (e.g., joint deformities, vision loss), highly active disease that causes major impairment in quality of life (i.e., active psoriatic inflammatory disease at many sites [including dactylitis,",
            "(e.g., joint deformities, vision loss), highly active disease that causes major impairment in quality of life (i.e., active psoriatic inflammatory disease at many sites [including dactylitis, enthesitis] or function-limiting inflammatory disease at few sites), and rapidly progressive disease. § Because there are currently no widely agreed-upon definitions of disease severity, psoriasis severity should be established by the health care provider and patient on a case-by-case basis. In clinical",
            "interferes with function (e.g., joint deformities, vision loss), highly active disease that causes major impairment in quality of life (i.e., active psoriatic inflammatory disease at many sites [including dactylitis, enthesitis] or function-limiting inflammatory disease at few sites), and rapidly progressive disease. ¶ Because there are currently no widely agreed-upon definitions of disease severity, psoriasis severity should be established by the health care provider and patient on a"
        ]
    },
    {
        "pregunta": "4. What are the poor prognostic factors that help define severe psoriatic arthritis?",
        "respuesta": "Poor prognostic factors that help define severe psoriatic arthritis (PsA) include:\n\n- Erosive disease  \n- Elevated levels of inflammation markers such as C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) attributable to PsA\n\nAdditionally, severe PsA may be indicated by:\n\n- Long-term damage that interferes with function (e.g., joint deformities, vision loss)  \n- Highly active disease causing major impairment in quality of life (including active inflammation at multiple sites such as dactylitis or enthesitis)\n\nThese factors collectively help identify patients with severe PsA who might require more aggressive treatment.",
        "contexto": [
            "care providers and patients should judge PsA and psoriasis severity on a case-bycase basis. For the purpose of these recommendations, severity includes not only the level of disease activity at a given time point, but also the presence or absence of poor prognostic factors and long-term damage. Examples of severe PsA disease include the presence of 1 or more of the following: a poor prognostic factor (erosive disease, dactylitis, elevated levels of inflammation mark-ers such as ESR and CRP",
            "of severe PsA disease include the presence of ≥1 of the following: a poor prognostic factor (erosive disease, elevated levels of inflammation markers such as C-reactive protein or erythrocyte sedimentation rate attributable to PsA), long-term damage that interferes with function (e.g., joint deformities, vision loss), highly active disease that causes major impairment in quality of life (i.e., active psoriatic inflammatory disease at many sites [including dactylitis, enthesitis] or",
            "it encompasses the level of disease activity at a given time point, as well as the presence of poor prognostic factors and long-term damage. Examples of severe PsA disease include the presence of ≥1 of the following: a poor prognostic factor (erosive disease, elevated levels of inflammation markers such as C-reactive protein or erythrocyte sedimentation rate attributable to PsA), long-term damage that interferes with function (e.g., joint deformities, vision loss), highly active disease that",
            "consideration all active disease domains, comorbidities, and the patient's functional status in choosing the optimal therapy for an individual at a given point in time. Examples of \"severe\" psoriatic arthritis (PsA) and psoriasis. The guideline development group defined severe PsA and psoriasis as the presence of 1 or more of the items listed. This is not a formal definition. There have been many definitions of severe psoriasis used over time-the items here are adapted from the 2007 National",
            "Area and Severity Index (PASI) score ( 25 have no contraindications to high-impact exercises ( DISCUSSION We present herein the first ACR/NPF guideline for the treatment of psoriatic arthritis. The goal of this guideline is to assist health care providers in managing active PsA in their patients, including optimizing therapy. PsA is a heterogene-ous and multifaceted inflammatory disease, and its different clinical features (e.g., peripheral arthritis, psoriasis, nail disease, enthesitis,"
        ]
    },
    {
        "pregunta": "5. What is the recommended treatment strategy for PsA patients with predominant enthesitis who are both OSM- and biologic-naive?",
        "respuesta": "For patients with active psoriatic arthritis (PsA) who have predominant enthesitis and are both OSM- and biologic-naive, the recommended treatment strategy is to start with a tumor necrosis factor inhibitor (TNFi) biologic agent over an oral small molecule (OSM) as a first-line option.\n\nIf the patient prefers oral therapy or has contraindications to TNFi biologics, apremilast (an OSM) may be used instead.\n\nAdditionally, oral NSAIDs are recommended over starting an OSM (such as apremilast) unless the patient has cardiovascular disease, peptic ulcer disease, renal impairment, or severe psoriasis/PsA.  \n\nTherefore, the general sequence is:\n\n1. TNFi biologic preferred first-line  \n2. Apremilast as an alternative if oral therapy is preferred or TNFi contraindicated  \n3. Oral NSAIDs preferred over OSM initially, unless comorbidities dictate otherwise\n\nThis approach is supported by the evidence primarily drawn from apremilast studies for enthesitis outcomes.",
        "contexto": [
            "in treatment-naive patients and despite treatment with an OSM (Table 5 In treatment-naive PsA patients with predominant enthesitis, a TNFi biologic is recommended over an OSM as a first-line option. Apremilast may be used instead of a TNFi biologic if the patient prefers an oral therapy or has contraindications to TNFi. Oral NSAIDs are recommended over starting an OSM unless the patient has cardiovascular disease, peptic ulcer disease, renal disease (or impairment), or severe psoriasis or PsA,",
            "|In adult patients with active PsA and predominant enthesitis who are both OSM- and biologic treatment–naive,¶| |\n|5. Start oral NSAIDs over an OSM (specifically apremilast) (PICO 48)|Very low|",
            "<h1>It should be noted that for the enthesitis questions (PICO 49, 50, and 51), the existing evidence was mainly drawn from the apremilast studies, as no randomized controlled trial report described enthesitis outcomes for the other OSMs.</h1>\n\n<h1>Table 6. Recommendations for treatment of patients with active psoriatic arthritis and comorbidities, including concomitant diabetes and recurrent serious infections (PICOs 63–66)*</h1>",
            "<h1>Table 1. Recommendations for the initial treatment of patients with active psoriatic arthritis who are OSM- and other treatment–naive (PICOs 9–15)*</h1>",
            "Supplementary Appendix 5 (on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40726/abstract Recommendations for pharmacologic interventions Active PsA in treatment-naive patients (Table 1 3 In treatment-naive patients with active PsA, a TNFi biologic agent is recommended over an OSM as a first-line option (Table 1 2 For treatment-naive patients with active PsA, the use of a TNFi biologic or OSM is recommended over an interleukin-17 inhibitor (IL-17i) or"
        ]
    },
    {
        "pregunta": "6. How is active psoriatic arthritis (PsA) defined according to the clinical guideline?",
        "respuesta": "Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on the presence of one or more of the following:\n\n- Swollen joints  \n- Tender joints  \n- Dactylitis  \n- Enthesitis  \n- Axial disease  \n- Active skin and/or nail involvement  \n- Extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD).",
        "contexto": [
            "* Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease. † When there were no published studies, we relied on the clinical",
            "<p>*Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD).</p>",
            "<p>*Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD).</p>",
            "<p>*Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD).</p>",
            "<p>*Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease.</p>"
        ]
    },
    {
        "pregunta": "7. Qual é a utilidade do índice PASI na avaliação da gravidade da psoríase em pacientes com PsA?",
        "respuesta": "O índice PASI (Psoriasis Area and Severity Index) é utilizado na avaliação da gravidade da psoríase em pacientes com artrite psoriásica (PsA) através da mensuração da extensão e da severidade das lesões cutâneas. Na prática clínica e em estudos clínicos, um escore PASI ≥ 25 tem sido usado para definir psoríase grave. Portanto, o PASI serve como uma medida objetiva para classificar a gravidade da psoríase, auxiliar na decisão terapêutica e avaliar respostas ao tratamento em pacientes com PsA.",
        "contexto": [
            "Area and Severity Index (PASI) score ( 25 have no contraindications to high-impact exercises ( DISCUSSION We present herein the first ACR/NPF guideline for the treatment of psoriatic arthritis. The goal of this guideline is to assist health care providers in managing active PsA in their patients, including optimizing therapy. PsA is a heterogene-ous and multifaceted inflammatory disease, and its different clinical features (e.g., peripheral arthritis, psoriasis, nail disease, enthesitis,",
            "(Figure 2 2 The panels chose the critical outcomes for all comparisons at the initial scoping; these included the American College of Rheumatology 20% response criteria (ACR20) (the primary outcome for most PsA clinical trials), the Health Assessment Questionnaire disability index (a measure of physical function), the PASI 75% response criteria (PASI75) (a measure of skin psoriasis improvement), and serious infections. Both the ACR20 and the PASI75 are accepted outcome mea sures specified by",
            "Both the ACR20 and the PASI75 are accepted outcome mea sures specified by regulatory agencies, including the US FDA, for the approval of treatments for PsA Moving from evidence to recommendations. GRADE methodology specifies that panels make recommendations based on the balance of benefits and harms, the quality of the evidence (i.e., confidence in effect estimates), and patients' values and preferences. Deciding on the balance between desirable and undesirable outcomes requires estimating the",
            "provider and patient on a case-by-case basis. In clinical trials, severe psoriasis has been defined as a Psoriasis Area and Severity Index (PASI) score ( 25 (Table 4 6 Treat-to-target (Table 5). This recommendation for patients with active PsA is conditional based on low-quality evidence. In patients with active PsA, using a treat-to-target strategy is recommended over not following a-treat-to-target strategy. One may consider not using a treat-to-target strategy in patients in whom there are",
            "Network recommendations for spondyloarthritis (SpA). § Because there are currently no widely agreed-upon definitions of disease severity, psoriasis severity should be established by the health care provider and patient on a case-by-case basis. In clinical trials, severe psoriasis has been defined as a Psoriasis Area and Severity Index (PASI) score ( 25 Table 5. (Cont'd) Active PsA with predominant enthesitis in treatment-naive patients and despite treatment with an OSM (Table 5 In"
        ]
    },
    {
        "pregunta": "8. Why are all recommendations regarding switching biologics in active PsA considered conditional and based on very-low-quality evidence?",
        "respuesta": "Todas as recomendações sobre a troca de biológicos em artrite psoriásica (PsA) ativa são consideradas condicionais e baseadas em evidências de qualidade muito baixa porque a maior parte dos dados disponíveis provém de evidências indiretas, estudos com baixo poder estatístico, ou extrapolações de outras doenças inflamatórias, como a artrite reumatoide. Assim, o painel de especialistas reconhece que o benefício líquido dessas intervenções é incerto, e há limitações significativas na confiabilidade dos resultados. Por essa razão, as recomendações refletem uma preferência que provavelmente se aplica à maioria dos pacientes, mas que deve ser individualizada, considerando o contexto clínico, custo, efeitos adversos e as preferências do paciente.",
        "contexto": [
            "|Conditional recommendation based on low-quality evidence; may consider not following a treat-to-target strategy in patients in whom higher frequency and/or severity of adverse events, higher cost of therapy, or higher patient burden of medications with tighter control are a concern.| |\n|In patients with active PsA with psoriatic spondylitis/axial disease despite treatment with NSAIDs,‡| |\n|2. Switch to a TNFi biologic over switching to an IL-17i biologic (PICO 46)|Very low|",
            "may be considered instead of an IL-17i or IL- Recommendations for the treatment of patients with active psoriatic arthritis (PsA) despite treatment with oral small molecules (OSMs). All recommendations are conditional based on low-to very-low-quality evidence. A conditional recommendation means that the panel believed the desirable effects of following the recommendation probably outweigh the undesirable effects, so the course of action would apply to the majority of the patients, but some may",
            "|---|---|\n|Conditional recommendation based on very-low-quality evidence; may consider switching to an IL-12/23i biologic and MTX combination therapy if the patient has severe psoriasis.|Conditional recommendation based on very-low-quality evidence; may consider switching to an IL-12/23i biologic and MTX combination therapy if the patient has severe psoriasis.|\n|14. Switch to a different TNFi biologic + MTX over switching to a different TNFi biologic monotherapy (PICO 33)|Very low|",
            "(a TNFi receptor biologic) and secukinumab (an IL-17i biologic) are not When the evidence was low or very-low quality, the panel could not be confident in the judgment of net benefit-thus the conditional recommendation. Often, low-or very-low-quality evidence came from indirect evidence, for instance from rheumatoid arthritis http://onlinelibrary.wiley.com/doi/10.1002/art.40726/ abstract We recognize that these recommendations do not account for the full complexity of PsA or the full range of",
            "|Conditional recommendation based on very-low-quality evidence; may consider adding MTX in patients in whom the severe psoriasis is not responding to the current therapy, or if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease.| |\n|8. Switch to an IL-17i biologic over adding MTX to an IL-12/23i biologic (PICO 37).|Very low|"
        ]
    },
    {
        "pregunta": "9. Which oral small molecules are considered in PsA treatment guidelines, and how is tofacitinib categorized differently?",
        "respuesta": "Nas diretrizes para o tratamento da artrite psoriásica (PsA), os medicamentos orais considerados incluem os chamados **fármacos orais pequenos (oral small molecules, OSM)**, como por exemplo o **apremilast**. Esses fármacos orais são recomendados como opções terapêuticas, especialmente quando o paciente prefere terapia oral ou apresenta contraindicações para biológicos.\n\nO **tofacitinibe**, embora seja um fármaco oral utilizado para PsA, é categorizado de forma diferente nas diretrizes porque, na época da formulação das recomendações, ele ainda não havia sido aprovado pelo FDA para PsA e, portanto, não foi incluído nas principais recomendações e nem nas perguntas PICO (População, Intervenção, Comparador, Outcome) analisadas para o guideline. Assim, o tofacitinibe não faz parte das recomendações formais atuais, e suas orientações específicas ainda serão abordadas em documentos posteriores.\n\nEm resumo:\n\n- **Medicamentos orais considerados**: fármacos orais pequenos (OSM), como apremilast.  \n- **Tofacitinibe**: classificado separadamente por estar em processo de aprovação na época das diretrizes, sem recomendações formais incluídas no documento principal.\n\nCaso precise de informações mais detalhadas sobre o uso de tofacitinibe, recomenda-se aguardar atualizações das diretrizes ou consultar literatura específica mais recente.",
        "contexto": [
            "management rather than addressing acute symptom management (i.e., through intraarticular injections and the use of systemic glucocorticoids). Tofacitinib and ixekizumab were submitted for review and potential approval by the US Food and Drug Administration (FDA) at the time of formulation of this guideline There are currently no widely agreed-upon definitions of disease severity in PsA or psoriasis. Thus, health care providers and patients should judge PsA and psoriasis severity on a",
            "<h1>Table 3. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with a TNFi biologic, as monotherapy or in combination with MTX (PICOs 26–35; 70–75)*</h1>",
            "<h1>Table 5. Recommendations for treatment of patients with active psoriatic arthritis including treat-to-target, active axial disease, enthesitis, or active inflammatory bowel disease (PICOs 44–55; 58–62)*</h1>",
            "makes it difficult to compare therapies across trials. The impact of alternative therapies on important outcomes such as joint damage still remains to be elucidated. Vaccination recommendations with tofacitinib were not included, as it was not yet approved for PsA when the PICO questions were drafted and only a limited number of PICO questions could be feasibly included for voting. Additional topics, including vaccination in the setting of tofacitinib, will be addressed in a subsequent",
            "Supplementary Appendix 5 (on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40726/abstract Recommendations for pharmacologic interventions Active PsA in treatment-naive patients (Table 1 3 In treatment-naive patients with active PsA, a TNFi biologic agent is recommended over an OSM as a first-line option (Table 1 2 For treatment-naive patients with active PsA, the use of a TNFi biologic or OSM is recommended over an interleukin-17 inhibitor (IL-17i) or"
        ]
    },
    {
        "pregunta": "10. Quais manifestações extraarticulares podem estar associadas à artrite psoriásica ativa?",
        "respuesta": "As manifestações extraarticulares que podem estar associadas à artrite psoriásica (PsA) ativa incluem **uveíte** e **doença inflamatória intestinal (DII)**.",
        "contexto": [
            "* Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease. † When there were no published studies, we relied on the clinical",
            "<p>*Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD).</p>",
            "<p>*Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD).</p>",
            "<p>*Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD).</p>",
            "<p>*Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease.</p>"
        ]
    },
    {
        "pregunta": "11. Describe the typical patterns of peripheral arthritis distribution seen in PsA.",
        "respuesta": "Os padrões típicos de distribuição da artrite periférica observados na artrite psoriásica (PsA) são:\n\n- Artrite assimétrica oligoarticular (envolvendo 4 ou menos articulações)  \n- Artrite poliarticular simétrica (envolvendo 5 ou mais articulações)\n\nAlém disso, as articulações interfalangeanas distais são comumente afetadas, podendo, em alguns pacientes, serem as únicas articulações acometidas.",
        "contexto": [
            "onycholysis, occur in ~80-90% of patients with PsA. The incidence of PsA is ~6 per 100,000 per year, and the prevalence is ~1-2 per 1,000 in the general population PsA affects men and women equally. The distribution of the peripheral arthritis varies from asymmetric oligoarthritis (involving ≤4 joints) to symmetric polyarthritis (involving ≥5 joints). Distal interphalangeal joints are commonly affected and, in some patients, are the only affected joints. Axial disease, when present, usually",
            "2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis      90D16D20B18D6C2F67C5D476A40ED8A9 10.1002/art.40726  INTRODUCTION Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis, manifesting most commonly with peripheral arthritis, dactylitis, enthesitis, and spondylitis. Nail lesions, including pitting and onycholysis, occur in ~80-90% of patients with PsA. The incidence of PsA",
            "<p>*Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD).</p>",
            "<p>*Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD).</p>",
            "<p>*Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD).</p>"
        ]
    },
    {
        "pregunta": "12. Quais são alguns exemplos de fatores prognósticos ruins na artrite psoriásica?",
        "respuesta": "Alguns exemplos de fatores prognósticos ruins na artrite psoriásica (PsA) incluem:\n\n- Doença erosiva  \n- Níveis elevados de marcadores inflamatórios atribuíveis à PsA, como proteína C-reativa (PCR) ou taxa de sedimentação de eritrócitos (VHS)\n\nEsses fatores, isoladamente ou em conjunto com outras características como dano a longo prazo que interfere na função (por exemplo, deformidades articulares, perda visual) ou doença altamente ativa com grande impacto na qualidade de vida, ajudam a definir a PsA grave.",
        "contexto": [
            "care providers and patients should judge PsA and psoriasis severity on a case-bycase basis. For the purpose of these recommendations, severity includes not only the level of disease activity at a given time point, but also the presence or absence of poor prognostic factors and long-term damage. Examples of severe PsA disease include the presence of 1 or more of the following: a poor prognostic factor (erosive disease, dactylitis, elevated levels of inflammation mark-ers such as ESR and CRP",
            "long-term damage. Examples of severe PsA disease include the presence of ≥1 of the following: a poor prognostic factor (erosive disease, elevated levels of inflammation markers such as C-reactive protein or erythrocyte sedimentation rate attributable to PsA), long-term damage that interferes with function (e.g., joint deformities, vision loss), highly active disease that causes major impairment in quality of life (i.e., active psoriatic inflammatory disease at many sites [including dactylitis,",
            "long-term damage. Examples of severe PsA disease include the presence of ≥1 of the following: a poor prognostic factor (erosive disease, elevated levels of inflammation markers such as C-reactive protein or erythrocyte sedimentation rate attributable to PsA), long-term damage that interferes with function (e.g., joint deformities, vision loss), highly active disease that causes major impairment in quality of life (i.e., active psoriatic inflammatory disease at many sites [including dactylitis,",
            "long-term damage. Examples of severe PsA disease include the presence of ≥1 of the following: a poor prognostic factor (erosive disease, elevated levels of inflammation markers such as C-reactive protein or erythrocyte sedimentation rate attributable to PsA), long-term damage that interferes with function (e.g., joint deformities, vision loss), highly active disease that causes major impairment in quality of life (i.e., active psoriatic inflammatory disease at many sites [including dactylitis,",
            "damage. Examples of severe PsA disease include the presence of ≥1 of the following: a poor prognostic factor (erosive disease, elevated levels of inflammation markers such as C-reactive protein or erythrocyte sedimentation rate attributable to PsA), long-term damage that interferes with function (e.g., joint deformities, vision loss), highly active disease that causes major impairment in quality of life (i.e., active psoriatic inflammatory disease at many sites [including dactylitis,"
        ]
    },
    {
        "pregunta": "13. What biologic therapies are recommended for active PsA patients with concomitant active inflammatory bowel disease (IBD)?",
        "respuesta": "Para pacientes com artrite psoriásica (PsA) ativa que apresentam doença inflamatória intestinal (DII) ativa concomitante, as diretrizes recomendam fortemente o uso de:\n\n- **Anticorpos monoclonais anti-TNF (TNFi)**,  \n- **Biológicos inibidores da interleucina 12/23 (IL-12/23i), como o ustekinumabe.**\n\nEssas recomendações baseiam-se em evidências de qualidade moderada demonstrando a eficácia tanto dos TNFi monoclonais quanto dos IL-12/23i no manejo da DII.\n\nEm contrapartida, os biológicos da classe IL-17i (ex.: secuquinumabe) e os TNFi do tipo receptor (ex.: etanercepte) **não são recomendados** para pacientes com DII ativa, pois não demonstraram eficácia nesta condição.\n\nPortanto, para PsA com DII ativa, priorizam-se TNFi monoclonais ou IL-12/23i biologics para otimizar o controle das duas doenças.",
        "contexto": [
            "<h1>Table 5. Recommendations for treatment of patients with active psoriatic arthritis including treat-to-target, active axial disease, enthesitis, or active inflammatory bowel disease (PICOs 44–55; 58–62)*</h1>",
            "<h1>Table 4. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with an IL-17i or an IL-12/23i biologic monotherapy (PICOs 36–43)*</h1>",
            "evidence showing IL-12/23i biologic is effective for IBD while an IL-17i biologic is not effective for IBD. * Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as",
            "of Psoriasis and Psoriatic Arthritis recommendations In patients with concomitant IBD, the Voting Panel made strong recommendations favoring a monoclonal antibody TNFi or an IL-12/23i biologic over an IL-17i biologic or a TNFi receptor biologic (etanercept). This was based on moderate-quality evidence showing that TNFi biologics and ustekinumab (an IL-12/23i biologic) are effective for the management of IBD, whereas etanercept (a TNFi receptor biologic) and secukinumab (an IL-17i biologic) are",
            "<h1>Table 3. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with a TNFi biologic, as monotherapy or in combination with MTX (PICOs 26–35; 70–75)*</h1>"
        ]
    },
    {
        "pregunta": "14. ¿Qué criterios se utilizan para decidir el cambio de tratamiento en pacientes con PsA activa a pesar del tratamiento con un OSM?",
        "respuesta": "Según las directrices disponibles, los criterios para decidir cambiar el tratamiento en pacientes con artritis psoriásica (PsA) activa a pesar del tratamiento con un fármaco oral pequeño (OSM) son principalmente clínicos y pueden incluir:\n\n- Persistencia de actividad inflamada que causa síntomas molestos o impacto significativo en la calidad de vida, evidenciado por manifestaciones como artritis, dactilitis, entesitis activa, o afectación cutánea o ungueal activa.\n- Inadecuada respuesta al OSM, reflejada en la falta de mejoría o progresión de los signos y síntomas inflamatorios.\n- Consideración de comorbilidades o factores que limitan el uso continuado del OSM.\n  \nEn estos casos, las recomendaciones condicionan el cambio a terapias biológicas, preferiblemente un inhibidor de factor de necrosis tumoral (TNFi) sobre un inhibidor de IL-17, con base en evidencia de baja a muy baja calidad.\n\nSin embargo, dado que las recomendaciones son condicionales y basadas en evidencia limitada, la decisión de cambiar el tratamiento debe ser individualizada y tomada mediante juicio clínico combinado con la valoración de preferencias del paciente.\n\n**Nota:** La información específica y detallada para definir criterios objetivos o puntajes claros para el cambio terapéutico tras fracaso de OSM no está disponible en el material proporcionado.",
        "contexto": [
            "<h1>It should be noted that for the enthesitis questions (PICO 49, 50, and 51), the existing evidence was mainly drawn from the apremilast studies, as no randomized controlled trial report described enthesitis outcomes for the other OSMs.</h1>\n\n<h1>Table 6. Recommendations for treatment of patients with active psoriatic arthritis and comorbidities, including concomitant diabetes and recurrent serious infections (PICOs 63–66)*</h1>",
            "<h1>Table 2. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with an OSM (PICOs 16–25; 67–69; 76–78)*</h1>",
            "may be considered instead of an IL-17i or IL- Recommendations for the treatment of patients with active psoriatic arthritis (PsA) despite treatment with oral small molecules (OSMs). All recommendations are conditional based on low-to very-low-quality evidence. A conditional recommendation means that the panel believed the desirable effects of following the recommendation probably outweigh the undesirable effects, so the course of action would apply to the majority of the patients, but some may",
            "<h1>Table 1. Recommendations for the initial treatment of patients with active psoriatic arthritis who are OSM- and other treatment–naive (PICOs 9–15)*</h1>",
            "|Conditional recommendation based on very-low-quality evidence; may consider starting an OSM (specifically apremilast) if the patient has recurrent infections.| |\n|In adult patients with active PsA and predominant enthesitis despite treatment with OSM,| |\n|8. Switch to a TNFi biologic over an IL-17i biologic (PICO 53)|Low (72, 73, 76, 89, 90, 92)|"
        ]
    },
    {
        "pregunta": "15. Em quais situações pode-se considerar a troca de um TNFi por um inibidor de IL-17 (IL-17i)?",
        "respuesta": "Pode-se considerar a troca de um inibidor do fator de necrose tumoral (TNFi) por um inibidor da interleucina 17 (IL-17i) no tratamento da artrite psoriásica nas seguintes situações, conforme as diretrizes condicionais baseadas em evidência de qualidade muito baixa a baixa:\n\n- Paciente com psoríase grave.  \n- Paciente com contraindicações aos biológicos TNFi, incluindo insuficiência cardíaca congestiva, infecções graves prévias, infecções recorrentes, doenças desmielinizantes (como esclerose múltipla) ou história familiar dessas condições.  \n- Paciente com falha secundária ao IL-17i atualmente utilizado (para troca entre IL-17i diferentes).  \n\nPortanto, a troca para IL-17i é considerada principalmente quando há contraindicações ao TNFi ou em casos específicos de psoríase grave, preferências individuais e tolerabilidade, sempre levando em conta a segurança e características clínicas do paciente.",
        "contexto": [
            "|2. Switch to a TNFi biologic over an IL-17i biologic (PICO 17)|Moderate (62–66, 72–78, 87–97)|\n|Conditional recommendation based on moderate-quality evidence; may consider an IL-17i if the patient has severe psoriasis and/or has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease, and/or a family history of demyelinating disease such as multiple sclerosis.| |",
            "|Conditional recommendation based on very-low-quality evidence; may consider switching to a different IL-17i if the patient had had a secondary efficacy failure to current IL-17i, or severe psoriasis, or contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease.| |\n|3. Switch to a TNFi biologic over adding MTX to an IL-17i biologic (PICO 41)|Very low|",
            "including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease, or prefers less frequent drug administration. Switch to a TNFi biologic over switching to a different IL-17i biologic (PICO 42) Very low Conditional recommendation based on very-low-quality evidence; may consider switching to a different IL-17i if the patient had had a secondary efficacy failure to current IL-17i, or severe psoriasis, or contraindications to TNFi biologics, including",
            "|Conditional recommendation based on low-quality evidence; may consider switching to an IL-17i if the patient has severe psoriasis or contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease.| |\n|9. Switch to a TNFi biologic over an IL-12/23i biologic (PICO 52)|Low (72, 73, 76, 98, 100)|",
            "|Conditional recommendation based on very-low-quality evidence; may consider an IL-17i if the patient has severe psoriasis or contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease.| |\n|7. Switch to a TNFi biologic over adding MTX to an IL-12/23i biologic (PICO 36)|Very low|"
        ]
    },
    {
        "pregunta": "16. Quais são as recomendações para a transição entre diferentes classes de biológicos em pacientes com resposta parcial ou falha primária ao tratamento atual?",
        "respuesta": "As recomendações para a troca entre diferentes classes de biológicos em pacientes com artrite psoriásica (PsA) que apresentam **resposta parcial ou falha primária** ao tratamento atual são todas **condicionais** e baseadas em **evidência de qualidade muito baixa a baixa**. Isso significa que as decisões devem ser individualizadas, considerando as características clínicas, efeitos adversos, preferências do paciente e julgamento clínico.\n\nDe forma geral, as principais orientações são:\n\n- **Após falha ou resposta insuficiente a um biológico inibidor de TNF (TNFi):**  \n  - É condicionalmente recomendado trocar para um biológico de outra classe, preferencialmente para um inibidor de IL-17 (IL-17i), em vez de tentar um outro TNFi.  \n  - A troca para um inibidor de IL-12/23 (IL-12/23i) também é uma opção, dependendo do contexto clínico.\n\n- **Após falha ou resposta insuficiente a um IL-17i ou IL-12/23i:**  \n  - Pode-se considerar a troca para um TNFi ou para outro biológico de classe diferente.\n\n- **Critérios de troca:**  \n  - Falha primária (ausência de resposta desde o início do tratamento) ou resposta parcial persistente, impactando o controle da doença.  \n  - Presença de contraindicações, comorbidades, ou efeitos adversos relacionados ao biológico em uso.\n\n- **Importante:**  \n  - As recomendações ressaltam que o benefício líquido da troca é incerto devido à qualidade limitada da evidência.  \n  - A decisão deve ser feita por meio de compartilhamento com o paciente, avaliando riscos, benefícios, custo e preferências pessoais.\n\nPortanto, na prática, a troca entre classes de biológicos em PsA é considerada especialmente nos casos em que o tratamento atual é insuficiente ou não tolerado, favorecendo a mudança para um agente com mecanismo diferente, mas sempre com base em decisão clínica individualizada e diálogo com o paciente.",
        "contexto": [
            "<h1>Table 3. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with a TNFi biologic, as monotherapy or in combination with MTX (PICOs 26–35; 70–75)*</h1>",
            "<h1>Table 4. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with an IL-17i or an IL-12/23i biologic monotherapy (PICOs 36–43)*</h1>",
            "<h1>Table 5. Recommendations for treatment of patients with active psoriatic arthritis including treat-to-target, active axial disease, enthesitis, or active inflammatory bowel disease (PICOs 44–55; 58–62)*</h1>",
            "<h1>Table 1. Recommendations for the initial treatment of patients with active psoriatic arthritis who are OSM- and other treatment–naive (PICOs 9–15)*</h1>",
            "<h1>Table 2. Recommendations for treatment of patients with active psoriatic arthritis despite treatment with an OSM (PICOs 16–25; 67–69; 76–78)*</h1>"
        ]
    },
    {
        "pregunta": "17. For patients with active PsA and predominant enthesitis who are treatment-naive, what is the initial recommended therapy?",
        "respuesta": "For patients with active psoriatic arthritis (PsA) who have predominant enthesitis and are both oral small molecule (OSM)– and biologic–naive, the guideline recommends starting treatment with a **tumor necrosis factor inhibitor (TNFi) biologic** over an OSM as a first-line option. \n\nIf the patient prefers oral therapy or has contraindications to TNFi biologics, **apremilast** (an OSM) may be used instead. Additionally, **oral NSAIDs** are recommended over starting an OSM initially, unless the patient has cardiovascular disease, peptic ulcer disease, renal impairment, or severe psoriasis/PsA. \n\nThus, the preferred initial therapy is:  \n1. TNFi biologic  \n2. If TNFi contraindicated or oral route preferred, apremilast  \n3. Start with oral NSAIDs before OSM unless contraindications exist\n\nThis recommendation is primarily based on evidence drawn from apremilast studies regarding enthesitis outcomes.",
        "contexto": [
            "<h1>Table 5. Recommendations for treatment of patients with active psoriatic arthritis including treat-to-target, active axial disease, enthesitis, or active inflammatory bowel disease (PICOs 44–55; 58–62)*</h1>",
            "<h1>It should be noted that for the enthesitis questions (PICO 49, 50, and 51), the existing evidence was mainly drawn from the apremilast studies, as no randomized controlled trial report described enthesitis outcomes for the other OSMs.</h1>\n\n<h1>Table 6. Recommendations for treatment of patients with active psoriatic arthritis and comorbidities, including concomitant diabetes and recurrent serious infections (PICOs 63–66)*</h1>",
            "in treatment-naive patients and despite treatment with an OSM (Table 5 In treatment-naive PsA patients with predominant enthesitis, a TNFi biologic is recommended over an OSM as a first-line option. Apremilast may be used instead of a TNFi biologic if the patient prefers an oral therapy or has contraindications to TNFi. Oral NSAIDs are recommended over starting an OSM unless the patient has cardiovascular disease, peptic ulcer disease, renal disease (or impairment), or severe psoriasis or PsA,",
            "|In adult patients with active PsA and predominant enthesitis who are both OSM- and biologic treatment–naive,¶| |\n|5. Start oral NSAIDs over an OSM (specifically apremilast) (PICO 48)|Very low|",
            "<li>Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD). TNFi = tumor necrosis factor inhibitor; MTX = methotrexate; IL-17i"
        ]
    },
    {
        "pregunta": "18. Why is etanercept not recommended as a first-line TNFi biologic in PsA patients with active IBD?",
        "respuesta": "O etanercepte não é recomendado como biológico inibidor do fator de necrose tumoral (TNFi) de primeira linha em pacientes com artrite psoriásica (PsA) e doença inflamatória intestinal (DII) ativa porque, segundo as diretrizes baseadas em evidência moderada, os TNFi do tipo receptor solúvel (como o etanercepte) não demonstraram eficácia no tratamento da DII. Por isso, em pacientes com PsA e DII ativa, são fortemente recomendados os anticorpos monoclonais anti-TNF (TNFi monoclonais) em vez do etanercepte para melhor manejo das duas condições concomitantes.",
        "contexto": [
            "of Psoriasis and Psoriatic Arthritis recommendations In patients with concomitant IBD, the Voting Panel made strong recommendations favoring a monoclonal antibody TNFi or an IL-12/23i biologic over an IL-17i biologic or a TNFi receptor biologic (etanercept). This was based on moderate-quality evidence showing that TNFi biologics and ustekinumab (an IL-12/23i biologic) are effective for the management of IBD, whereas etanercept (a TNFi receptor biologic) and secukinumab (an IL-17i biologic) are",
            "or contraindications to TNFi. An IL-17i biologic is recommended over an IL-12/23i biologic. An IL-12/23i biologic may be used instead of a TNFi biologic in patients who prefer less frequent drug administration, and instead of an IL-17i biologic in patients with concomitant IBD or who prefer less frequent drug administration. Active PsA with concomitant active IBD (Table 5). All recommendations for patients with active PsA with concomitant active IBD are strong based on moderate-quality",
            "molecule/soluble receptor biologic) is recommended over an OSM (Table 5 Active PsA despite treatment with an OSM in patients with concomitant active IBD. In patients with active PsA with concomitant active IBD despite treatment with an OSM, a monoclonal antibody TNFi biologic or an IL-12/23i biologic should be used over an IL-17i biologic, and a monoclonal antibody TNFi biologic should be used over a TNFi soluble receptor biologic (etanercept) (all strong recommendations [Table 5 Active PsA",
            "evidence showing IL-12/23i biologic is effective for IBD while an IL-17i biologic is not effective for IBD. * Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as",
            "|In adult patients with active PsA and concomitant active IBD despite treatment with an OSM,|In adult patients with active PsA and concomitant active IBD despite treatment with an OSM,|\n|15. Switch to a monoclonal antibody TNFi biologic over a TNFi biologic soluble receptor biologic (i.e., etanercept) (PICO 58)|Moderate (115–117)|"
        ]
    },
    {
        "pregunta": "19. What clinical features are included in the assessment of PsA severity?",
        "respuesta": "As características clínicas incluídas na avaliação da gravidade da artrite psoriásica (PsA) são:\n\n- Presença de doença erosiva (lesões radiográficas de destruição articular)\n- Níveis elevados de marcadores inflamatórios relacionados à PsA, como proteína C-reativa (PCR) e taxa de sedimentação de eritrócitos (VHS)\n- Dano a longo prazo que interfere na função, como deformidades articulares ou perda visual\n- Doença altamente ativa, causando impacto significativo na qualidade de vida, incluindo envolvimento ativo em múltiplos sítios (ex.: dactilite ou entesite ativa)\n\nEsses fatores ajudam a identificar pacientes com PsA grave que podem necessitar de tratamento mais agressivo.",
        "contexto": [
            "<p>*Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD).</p>",
            "<p>*Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD).</p>",
            "<p>*Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD).</p>",
            "<p>*Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease.</p>",
            "<p>*Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease.</p>"
        ]
    },
    {
        "pregunta": "20. Under what circumstances might switching from an IL-17 inhibitor to an IL-12/23 inhibitor be considered instead of switching to a TNF inhibitor?",
        "respuesta": "Pode-se considerar a troca de um inibidor de IL-17 por um inibidor de IL-12/23 em vez de trocar para um inibidor do fator de necrose tumoral (TNFi) nas seguintes circunstâncias:\n\n- Quando o paciente apresenta **contraindicações aos biológicos TNFi**, tais como insuficiência cardíaca congestiva, infecções graves prévias, infecções recorrentes ou doenças desmielinizantes.\n- Quando o paciente prefere uma **menor frequência de administração do medicamento**.\n\nEssa recomendação é condicional e baseada em evidência de qualidade muito baixa, mas sugere-se o uso de IL-12/23i biologic em vez de trocar para um TNFi nestes contextos específicos.",
        "contexto": [
            "evidence; may consider switching to an IL-12/23i biologic if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease, or prefers less frequent drug administration. 18. Switch to an IL-12/23i biologic over switching to an IL-17i biologic (PICO 60) Moderate ( 50 Strong recommendation supported by moderate-quality evidence showing IL-12/23i biologic is effective for IBD while an IL-17i",
            "or if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease. Switch to an IL-12/23i biologic over switching to a different IL-17i biologic (PICO 43) Very low Conditional recommendation based on very-low-quality evidence; may consider switching to a different IL-17i if the patient had had a secondary efficacy failure to current IL-17i or severe psoriasis, ‡ or if the patient has",
            "|Conditional recommendation based on very-low-quality evidence; may consider switching to IL-12/23i if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease, or prefers less frequent drug administration.| |\n|2. Switch to a TNFi biologic over switching to a different IL-17i biologic (PICO 42)|Very low|",
            "inhibitors (IL-17i), and IL-12/23i; patients may have received nonsteroidal antiinflammatory drugs (NSAIDs), glucocorticoids, and/or other pharmacologic and nonpharmacologic interventions.</p>",
            "IL-12/23i biologic if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease, or prefers less frequent drug administration.|"
        ]
    }
]